Sean F. Moran
Known title: Chief Financial OfficerCIK: 0001451495
Sean F. Moran's purchase track record
How the stock did after each of Sean F. Moran's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since March 10, 2022
Stock higher 6 months later
0%
3 months: 0%
Median 6-month return
-47.6%
3 months: -21.6%
Beat the S&P 500
0%
median -41.7% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/10/2022 | CRBP | $5K | -51.0% | -32.6% | -2.2% |
| 5/16/2022 | CRBP | $4K | -13.8% | -53.4% | -1.3% |
| 3/10/2022 | CRBP | $6K | -21.6% | -47.6% | -5.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CRBP | ▼ Sell | Open Market | 12,000 | $121K | 8/7/2026 | View on chart |
| CRBP | ▼ Sell | Open Market | 4,701 | $37K | 2/13/2026 | View on chart |
| CRBP | ▲ Buy | Grant | 28,082 | $0 | 1/14/2026 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 12,981 | $55K | 10/24/2025 | View on chart |
| CRBP | ▼ Sell | Open Market | 12,981 | $221K | 10/24/2025 | View on chart |
| CRBP | ▼ Sell | Open Market | 2,792 | $24K | 2/14/2025 | View on chart |
| CRBP | ▲ Buy | Grant | 27,500 | $0 | 1/31/2025 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 1,958 | $59K | 6/18/2024 | View on chart |
| CRBP | ▼ Sell | Open Market | 1,958 | $82K | 6/18/2024 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 6,730 | $95K | 6/17/2024 | View on chart |
| CRBP | ▼ Sell | Open Market | 6,730 | $315K | 6/17/2024 | View on chart |
| CRBP | ▼ Sell | Open Market | 1,567 | $78K | 6/14/2024 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 7,788 | $33K | 6/14/2024 | View on chart |
| CRBP | ▼ Sell | Open Market | 7,788 | $388K | 6/14/2024 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 1,567 | $47K | 6/14/2024 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 1,787 | $54K | 4/10/2024 | View on chart |
| CRBP | ▲ Buy | Grant | 40,176 | $0 | 2/12/2024 | View on chart |
| CRBP | ▲ Buy | Open Market | 20,000 | $5K | 8/10/2022 | View on chart |
| CRBP | ▲ Buy | Open Market | 12,000 | $4K | 5/16/2022 | View on chart |
| CRBP | ▲ Buy | Open Market | 15,000 | $6K | 3/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Corbus Doses First Patient in CRB-701 TEMPO-1 Study
Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.
Corbus Doses First Patient in CRB-701 TEMPO-1 Study. Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.